January 23, 2012
C‐Path receives approval from the European Medicines Agency (EMA) for imaging biomarker as a qualified measure to select patients with early stage cognitive impairment for Alzheimer’s disease clinical trials.
C‐Path receives approval from the European Medicines Agency (EMA) for imaging biomarker as a qualified measure to select patients with early stage cognitive impairment for Alzheimer’s disease clinical trials.
